SG11201406142XA - Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage - Google Patents
Compositions and methods for the prevention and treatment of mast cell-induced vascular leakageInfo
- Publication number
- SG11201406142XA SG11201406142XA SG11201406142XA SG11201406142XA SG11201406142XA SG 11201406142X A SG11201406142X A SG 11201406142XA SG 11201406142X A SG11201406142X A SG 11201406142XA SG 11201406142X A SG11201406142X A SG 11201406142XA SG 11201406142X A SG11201406142X A SG 11201406142XA
- Authority
- SG
- Singapore
- Prior art keywords
- prevention
- compositions
- treatment
- methods
- mast cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/175—Bunyaviridae, e.g. California encephalitis virus, Rift valley fever virus, Hantaan virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
- G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261616062P | 2012-03-27 | 2012-03-27 | |
PCT/US2013/032553 WO2013148366A1 (en) | 2012-03-27 | 2013-03-15 | Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201406142XA true SG11201406142XA (en) | 2014-10-30 |
Family
ID=49261101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201406142XA SG11201406142XA (en) | 2012-03-27 | 2013-03-15 | Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage |
Country Status (6)
Country | Link |
---|---|
US (2) | US9730921B2 (en) |
AU (1) | AU2013240220B2 (en) |
BR (1) | BR112014024287A2 (en) |
IN (1) | IN2014KN02323A (en) |
SG (1) | SG11201406142XA (en) |
WO (1) | WO2013148366A1 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
WO2011038397A2 (en) | 2009-09-28 | 2011-03-31 | Duke University | Peptide adjuvants, vaccines, and methods of use |
BR112014024287A2 (en) | 2012-03-27 | 2018-05-08 | Duke University | compositions and methods for the prevention and treatment of mast cell-induced vascular leakage |
CN105517631A (en) | 2013-03-13 | 2016-04-20 | 炎症反应研究公司 | Use of levocetirizine and montelukast in the treatment of traumatic injury |
RU2015134422A (en) | 2013-03-13 | 2017-04-18 | Инфламматори Респонс Ресёрч, Инк. | APPLICATION OF LEVOCYTHIRIZINE AND MONTELUKAST IN THE TREATMENT OF VASCULITIS |
CA2901421A1 (en) | 2013-03-13 | 2014-10-09 | Bruce Chandler May | Use of levocetirizine and montelukast in the treatment of autoimmune disorders |
CN103630645B (en) * | 2013-11-27 | 2016-08-17 | 中国检验检疫科学研究院 | A kind of measure the Liquid Chromatography-Tandem Mass Spectrometry of diphenhydramine content in cosmetics |
EP3102200B1 (en) * | 2014-02-07 | 2023-04-05 | Exithera Pharmaceuticals Inc. | Therapeutic compounds and compositions |
US20160367520A1 (en) | 2014-02-10 | 2016-12-22 | Patara Pharma, LLC | Mast cell stabilizers for lung disease treatment |
PL3104853T3 (en) | 2014-02-10 | 2020-05-18 | Respivant Sciences Gmbh | Mast cell stabilizers treatment for systemic disorders |
CN103735546A (en) * | 2014-02-11 | 2014-04-23 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Novel application of 4-oxo-8-[4-(4-phenyl butoxyl) benzamido]-2-tetrazol-4H-1-benzopyran-semihydrate |
DE102014111892A1 (en) * | 2014-08-20 | 2016-02-25 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Prophylaxis and treatment of hantavirus infection |
JP2017526728A (en) * | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | Levocetirizine and montelukast in the treatment of inflammation-mediated conditions |
WO2016102941A1 (en) | 2014-12-22 | 2016-06-30 | Rspr Pharma Ab | New combination of pemirolast and montelukast |
WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
US10702571B2 (en) | 2015-12-03 | 2020-07-07 | The University Of North Carolina At Pembroke | Materials for cathepsin B enhancement and methods of use |
CN109963865A (en) * | 2016-07-19 | 2019-07-02 | 阿雷特发现公司 | For detecting and treating the biomarker of mast cell activity associated disease |
AU2017321782B2 (en) | 2016-08-31 | 2022-03-10 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
JP2019528320A (en) | 2016-08-31 | 2019-10-10 | レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh | Cromolyn composition for the treatment of chronic cough due to idiopathic pulmonary fibrosis |
CN109803724A (en) | 2016-10-07 | 2019-05-24 | 瑞思皮万特科学有限责任公司 | For treating the Cromoglycic acid composition of pulmonary fibrosis |
CN106511346A (en) * | 2016-12-08 | 2017-03-22 | 上海市公共卫生临床中心 | Small molecular drug capable of being used for inhibiting Zika virus infection and application of drug |
BR112019015721A2 (en) | 2017-01-30 | 2020-03-24 | Western New England University | TIOL INHIBITORS ISOMERASES AND USE OF THE SAME |
CN108872405B (en) * | 2017-05-11 | 2021-06-01 | 武汉先路医药科技股份有限公司 | HPLC analysis detection method for relative substances of lodoxylamine tromethamine |
CN111886025A (en) * | 2017-11-01 | 2020-11-03 | 新加坡国立大学 | Use of serotonergic agents for the treatment of virus-induced thrombocytopenia |
BR112020016123A2 (en) | 2018-02-07 | 2021-02-23 | eXIthera Pharmaceuticals Inc. | therapeutic compounds and compositions |
KR102269663B1 (en) * | 2018-04-27 | 2021-06-28 | 주식회사 레모넥스 | Medicinal composition for preventing or treating flavivirus infections and method for treating the same |
WO2020051322A1 (en) * | 2018-09-05 | 2020-03-12 | The General Hospital Corporation | Methods of treating cytokine release syndrome |
MX2018011699A (en) | 2018-09-26 | 2019-07-24 | Federico Amezcua Amezcua | A synergistic pharmaceutical composition of leukotriene receptor antagonist and a histamine h1 inverse agonist. |
CN110237074B (en) * | 2019-07-25 | 2021-09-21 | 中国科学院武汉病毒研究所 | Application of benidipine in preparation of medicine for preventing and/or treating bunidipine virus infectious diseases |
EP4175647A4 (en) * | 2020-07-06 | 2024-08-07 | Crescenta Biosciences | Antiviral use of fabp4 modulating compounds |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2061862A1 (en) | 1991-03-04 | 1992-09-05 | Jonathan Duvick | Natural and synthetic proteins with inhibitory activity towards pathogenic microorganisms |
AU2514592A (en) | 1991-08-21 | 1993-03-16 | Board Of Regents, The University Of Texas System | Methods and compositions for modulating g protein action |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
IL140473A0 (en) | 2000-12-21 | 2002-02-10 | Allergene Ltd | Anti-allergic complex molecules |
US20020041898A1 (en) | 2000-01-05 | 2002-04-11 | Unger Evan C. | Novel targeted delivery systems for bioactive agents |
DE10055375A1 (en) * | 2000-11-08 | 2002-05-23 | Infineon Technologies Ag | Evaluation circuit for alternating voltage pulses detects alternating voltage pulse using sampled values from analogue to digital converter unit multiplied by mixing frequency |
EP1601379A1 (en) | 2003-02-13 | 2005-12-07 | Licentia OY | Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses |
EP1601380A1 (en) * | 2003-02-13 | 2005-12-07 | Licentia OY | Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia |
US8076059B2 (en) | 2003-04-16 | 2011-12-13 | Duke University | Adjuvant capable of specifically activating the adaptive immune response |
GB0427267D0 (en) | 2004-12-13 | 2005-01-12 | Maria Teresa De Magistris | Peptide adjuvants |
WO2006091610A2 (en) * | 2005-02-23 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Inhibitors of enveloped virus infectivity |
CA2698783A1 (en) | 2007-09-11 | 2009-03-19 | Dorian Bevec | Use of a peptide as a therapeutic agent |
US8080518B2 (en) | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
WO2011038397A2 (en) | 2009-09-28 | 2011-03-31 | Duke University | Peptide adjuvants, vaccines, and methods of use |
AU2011237679B2 (en) | 2010-04-07 | 2014-11-06 | Abbvie Inc. | TNF-alpha binding proteins |
BR112014024287A2 (en) | 2012-03-27 | 2018-05-08 | Duke University | compositions and methods for the prevention and treatment of mast cell-induced vascular leakage |
-
2013
- 2013-03-15 BR BR112014024287-9A patent/BR112014024287A2/en not_active IP Right Cessation
- 2013-03-15 WO PCT/US2013/032553 patent/WO2013148366A1/en active Application Filing
- 2013-03-15 SG SG11201406142XA patent/SG11201406142XA/en unknown
- 2013-03-15 US US14/388,140 patent/US9730921B2/en active Active
- 2013-03-15 AU AU2013240220A patent/AU2013240220B2/en active Active
-
2014
- 2014-10-21 IN IN2323KON2014 patent/IN2014KN02323A/en unknown
-
2017
- 2017-07-12 US US15/648,119 patent/US10668059B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2013240220B2 (en) | 2017-07-20 |
US20150038530A1 (en) | 2015-02-05 |
IN2014KN02323A (en) | 2015-05-01 |
WO2013148366A1 (en) | 2013-10-03 |
AU2013240220A1 (en) | 2014-10-16 |
US20170368050A1 (en) | 2017-12-28 |
US9730921B2 (en) | 2017-08-15 |
US10668059B2 (en) | 2020-06-02 |
BR112014024287A2 (en) | 2018-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201406142XA (en) | Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage | |
IL266582A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
HK1210957A1 (en) | Effluz inhibitor compositions and methods of treatment using the same | |
HK1209788A1 (en) | Methods and compositions for the treatment of lysosomal storage diseases | |
HK1204461A1 (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
EP2832366A4 (en) | Pharmaceutical composition for treatment and/or prevention of gall bladder cancer | |
EP2847152A4 (en) | Compositions and methods for the treatment of metabolic syndrome | |
IL225471A0 (en) | Compositions and methods for the prevention and treatment of cancer | |
IL238177A0 (en) | Methods and compositions for the treatment of cancer | |
EP2825242A4 (en) | Devices and methods for the treatment of vascular defects | |
EP2938289A4 (en) | Devices and methods for the treatment of vascular defects | |
ZA201408056B (en) | Compositions and methods for the treatment of mucositis | |
GB201217296D0 (en) | Method of treatment and/or prevention | |
EP2558085A4 (en) | Compositions and methods for the prevention and treatment of cancer | |
ZA201408055B (en) | Compositions and methods for the treatment of local pain | |
HK1201045A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP2828241A4 (en) | Compositions and methods for inhibition of cathepsins | |
HK1211221A1 (en) | Formulations for the treatment and prevention of obesity | |
PL3082845T3 (en) | Methods and compositions for treatment of peripheral neuropathies | |
ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
IL238602A0 (en) | Compositions and methods for the treatment of ectodermal dysplasia | |
HK1216721A1 (en) | Uses and methods for the treatment of liver diseases or conditions | |
ZA201408058B (en) | Compositions and methods for the treatment of epilepsy | |
ZA201408065B (en) | Compositions and methods for the treatment of diabetes | |
ZA201408053B (en) | Compositions and methods for the treatment of metabolic syndrome |